Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


1 Ann Surg Oncol
1 Clin Cancer Res
1 Clin Exp Metastasis
1 J Am Acad Dermatol
1 Lancet Oncol
2 Melanoma Res
1 N Engl J Med
1 Oncogene
1 Oncol Rep
1 Ophthalmology
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Surg Oncol

  1. PARK JS, Ng KS, Saw RPM, Thompson JF, et al
    Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience.
    Ann Surg Oncol. 2018 Apr 24. pii: 10.1245/s10434-018-6451.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  2. JOSEPH RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, et al
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-2386.
    PubMed     Text format     Abstract available

    Clin Exp Metastasis

  3. WEIDMANN C, Berube J, Piquet L, de la Fouchardiere A, et al
    Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.
    Clin Exp Metastasis. 2018 Apr 25. pii: 10.1007/s10585-018-9894.
    PubMed     Text format     Abstract available

    J Am Acad Dermatol

  4. YEN H, Li WQ, Dhana A, Li T, et al
    Red meat and processed meat intake and risk of cutaneous melanoma in white women and men: Two prospective cohort studies.
    J Am Acad Dermatol. 2018 Apr 23. pii: S0190-9622(18)30635.
    PubMed     Text format     Abstract available

    Lancet Oncol

  5. DAS M
    Novel gene variant for melanoma predisposition.
    Lancet Oncol. 2018 Apr 19. pii: S1470-2045(18)30319.
    PubMed     Text format    

    Melanoma Res

  6. MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
    Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Melanoma Res. 2018;28:256-257.
    PubMed     Text format    

  7. SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
    Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
    Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
    PubMed     Text format     Abstract available

    N Engl J Med

  8. More on Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:1656-1657.
    PubMed     Text format    


  9. REYES-URIBE P, Adrianzen-Ruesta MP, Deng Z, Echevarria-Vargas I, et al
    Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0247.
    PubMed     Text format     Abstract available

    Oncol Rep

  10. LI H, Chen J, Wang X, He M, et al
    Nodal induced by hypoxia exposure contributes to dacarbazine resistance and the maintenance of stemness in melanoma cancer stemlike cells.
    Oncol Rep. 2018 Apr 23. doi: 10.3892/or.2018.6387.
    PubMed     Text format     Abstract available


  11. DAMATO B
    Predicting Choroidal Melanoma Regression after Brachytherapy.
    Ophthalmology. 2018;125:755-756.
    PubMed     Text format    

    PLoS One

  12. LIU H, Weber A, Morse J, Kodumudi K, et al
    T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
    PLoS One. 2018;13:e0196033.
    PubMed     Text format     Abstract available

  13. YU C, Yang S, Kim W, Jung J, et al
    Correction: Acral melanoma detection using a convolutional neural network for dermoscopy images.
    PLoS One. 2018;13:e0196621.
    PubMed     Text format     Abstract available

  14. HUANG YX, Song H, Tao Y, Shao XB, et al
    Ovostatin 2 knockdown significantly inhibits the growth, migration, and tumorigenicity of cutaneous malignant melanoma cells.
    PLoS One. 2018;13:e0195610.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.